Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
Status:
Recruiting
Trial end date:
2026-08-31
Target enrollment:
Participant gender:
Summary
The goal of this single-arm, prospective study is to test in low-burden B-cell lymphoblastic
leukemia (B-ALL) patients undergoing allogeneic hemopoietic stem-cell transplantation
(allo-HSCT). The main question it aims to answer is:
• The efficacy and safety of short-term blinatumomab as a bridging therapy to allo-HSCT in
patients with low-burden B-ALL. Participants will take intravenous blinatumomab prior to
allo-HSCT with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day and
continued for 5 to 10 days. Dexamethasone 20mg was administered 1 hour before the onset of
blinatumomab infusion.